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This work was part of the inaugural disserta-
tion performed by E. Tuma.
Dear Sir,
Compelling evidence has accumulated
that monocyte-derived cytokines, particu-
larly the interleukin (IL) 1 family, play a
pathogenetic role in acute (fever, hypoten-
sion) and long-term complications of hemo-
dialysis (susceptibility to infections, athero-
sclerosis, and amyloidosis). IL-1· and IL-1ß
are potent proinflammatory mediators. The
IL-1 receptor antagonist (RA) is concurrent-
ly released with IL-1. The IL-1 RA is a spe-
cific inhibitor and acts by binding to IL-1
cell surface receptors without triggering a
biological response. A number of studies
reported elevated (3- to 5-fold) plasma IL-1
RA levels and increased cellular IL-1 RA
production in dialysis patients [1, 2]. It is
presently unknown whether the IL-1 RA
production changes with modifications of
the dialysis membrane or alterations of the
quality of the dialysate. Studies reported
either unchanged [3, 4], decreased [5], or
increased [6] IL-1 RA production and plas-
ma levels during hemodialysis sessions. The
discrepancy between these data may be relat-
ed to both methodological and biological dif-
ferences among the patients participating in
these studies.
The aim of the present study was to com-
pare the effects of membranes differing in
their potential to activate complement and
monocytes on dialysis-induced changes in
the cytokine production by monocytes and
to assess which parameters of IL-1 RA pro-
duction (cellular release after endotoxin
stimulation by peripheral blood mononu-
clear cells or by whole blood) are better sur-
rogate markers for dialysis membrane bioin-
compatibility. As plasma values correlate
best with residual renal function and clear-
ance in hemodialysis patients and not with
the activation of mononuclear cells, the ex
vivo production by mononuclear cell ap-
pears to be a better method to study IL-1 RA
as a marker of activation [7].
Six stable dialysis patients (4 men and
2 women, age range 40–72 years) partici-
pated in a crossover comparison of a bio-
compatible high-flux synthetic membrane
(Arylane 4, polyarylether sulfone, surface
area 1.35 m2; Hospal, Meyzières, France)
and a bioincompatible low-flux cellulosic
membrane (Disscap 150, cuprophane, sur-
face area 1.3 m2; Hospal).
They had received hemodialysis for an
average of 55 (range 13–81) months. The
patients’ treatment sessions lasted 4 h three
times per week. Dialysis was performed with
dialysis fluid produced by reverse osmosis
(mean number of colony-forming units 20/
ml, range 0–40 ml) mixed with commercial
bicarbonate and acid concentrates by pro-
portioning systems. Ultrafiltration was volu-
metrically controlled (MTS 4008; Fresenius,
Oberursel, Germany). Vascular access to the
extracorporeal circulation was via fistulae.
The cause of end-stage renal disease was
chronic glomerulonephritis in 2 patients,
hypertensive nephroangiosclerosis in 2 pa-
tients, and polycystic kidney disease or Bal-
kan nephritis in 1 patient each. None of the
patients had an acute infection, a chronic
inflammatory disorder, or malignancy. They
all received recombinant human erythropoi-
etin to achieve hemoglobin target levels of
10–11 g/dl. Blood samples for the determi-
nation of circulating leukocytes, comple-
ment compound C5a (Behringwerke, Mar-
burg, Germany), and IL-1 RA production
(R&D Systems, Minneapolis, Minn., USA)
after endotoxin stimulation (10 ng/ml) of
mononuclear cells or whole blood were taken
at the start of the dialysis session, 20 min
after initiation of dialysis, and at the end
of the dialysis session. Data for each of these
time points are shown in table 1.
During the early phase of cuprophane
dialysis, there was a rapid and pronounced
drop in circulating white blood cell count
caused by a drop in neutrophils and mono-
cytes. At the end of cuprophane dialysis,
there was a slight overshoot of the white
blood cell count. By contrast, the synthetic
membrane caused only a slight, but statisti-
cally not significant change in white blood
cell count. Cuprophane membranes induced
a sharp rise of complement compound C5a
after 20 min which decreased towards the
end of treatment, but did not normalize. The
use of the polyarylether sulfone membrane
was associated with a slight increase in this
compound, resulting from activation of the
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Table 1. Changes in white blood cell count, complement C5a, and IL-1 RA release during hemodialysis using membranes with different
biocompatibility (mean B SEM)
Membrane
cuprophane
0 min 20 min 240 min
Arylane
0 min 20 min 240 min
6.7B0.5 2.2B0.2* 7.2B1.1 6.8B0.4 6.5B0.8 5.7B0.7
Complement C5a, ng/ml 0.62B0.08 15.34B3.14* 3.14B0.51 0.52B0.07 0.77B0.14 0.98B0.23
IL-1 RA, pg/ml
Whole blood 20,658B4,223 1,246B173 16,043B2,059 24,698B4,150 11,371B5,056 17,610B4,028
Mononuclear cells 46,901B5,854 19,978B6,504 66,143B4,624* 49,860B12,871 41,493B9,713 38,552B8.765
* p ! 0.01 versus corresponding parameters.
alternate pathway of the complement sys-
tem. While both membranes did not signifi-
cantly alter IL-1 RA production in whole
blood, the use of the cuprophane membrane
induced a significant rise in the cellular pro-
duction of IL-1 RA by mononuclear cells.
Our study using dialyzer membranes
with different capability to induce comple-
ment and cell activation, in conjunction with
low levels of dialysis fluid contamination,
demonstrated a significant increase of cellu-
lar IL-1 RA release during clinical hemo-
dialysis with new cuprophane membranes.
These data support the widely accepted hy-
pothesis of a complement- or membrane-
induced transcriptional signal, followed by
endotoxin-induced translational stimulus in
bicarbonate dialysis fluid.
The notion of dialysis-induced increases
in cellular IL-1 RA production using cellu-
losic but not synthetic membranes is largely
in agreement with two other observations.
The first is that new and reused cuprophane
membranes were associated with raised IL-1
RA production during the early phase of the
dialysis session (drop in cellular production
at time point 20 min) [8]. The second is that
cellulosic membranes caused a significant
and polysulfone only a mild change at the
end of dialysis [6]. This dialysis-induced in-
crease demonstrates the bioincompatibility
of cuprophane membranes and conversely
shows the biocompatibility of polyarylether
sulfone membranes.
Discrepancies between other studies may
be explained by different methods used as
well as by differences in patients studied (nu-
tritional status, erythropoietin, presence of
infections or inflammation). All previous
studies failed to detect significant changes in
plasma IL-1 RA concentrations. Therefore,
the whole-blood stimulation system could
have been an alternative surrogate marker
for hemodialysis bioincompatibility, since it
does not require an isolation procedure. The
present study demonstrates that determina-
tion of mononuclear cell released IL-1 RA
still represents a better indicator of the host
response to cytokine stimuli encountered
during bioincompatible hemodialysis than
determination of IL-1 RA production in
stimulated whole blood.
The high IL-1 RA levels appear to be
mostly an expression of the inflammatory
state which hemodialysis resembles rather
than to have a pathogenetic role. In fact, it
has been shown that as much as a 100-fold to
1,000-fold excess of IL-1 RA concentration
and not a 3- to 5-fold increase in predialysis
or postdialysis levels, respectively, is re-
quired to inhibit IL-1-induced responses in
T lymphocytes and other target cells [9].
The cellular production of IL-1 RA is a
sensitive marker of membrane- and dialy-
sate-induced mononuclear cell stimulation
and may serve as a new surrogate marker for
the total hemodialysis procedure. Long-term
clinical studies will have to show whether
this marker correlates with clinical manifes-
tations of cytokine release such as prema-
ture development of atherosclerosis or amy-
loidosis.
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